BACKGROUND: Recurrent aphthous stomatitis (RAS) is a common disorder with hitherto unsatisfactory drug therapy. OBJECTIVE: Our purpose was to evaluate the prophylactic effect of colchicine in the treatment of RAS. METHODS: An open, prospective, 4-month study was conducted in 20 patients with RAS who served as their own controls. During the first 2 months of the study no medications were given and in the last 2 months colchicine, 1.5 mg/day, was prescribed. RESULTS: The mean number of aphthae per week and the subjective daily pain scores were reduced by 71% and 77%, respectively, during colchicine treatment as compared with the previous period (p < 0.001 for both). No serious side effects of colchicine were noted. CONCLUSION: These findings suggest a role for continuous colchicine therapy in the prevention of RAS.
BACKGROUND: Recurrent aphthous stomatitis (RAS) is a common disorder with hitherto unsatisfactory drug therapy. OBJECTIVE: Our purpose was to evaluate the prophylactic effect of colchicine in the treatment of RAS. METHODS: An open, prospective, 4-month study was conducted in 20 patients with RAS who served as their own controls. During the first 2 months of the study no medications were given and in the last 2 months colchicine, 1.5 mg/day, was prescribed. RESULTS: The mean number of aphthae per week and the subjective daily pain scores were reduced by 71% and 77%, respectively, during colchicine treatment as compared with the previous period (p < 0.001 for both). No serious side effects of colchicine were noted. CONCLUSION: These findings suggest a role for continuous colchicine therapy in the prevention of RAS.
Authors: Sohi Kang; Eun Joo Jang; Hyun Min Jo; Seong Soo Kang; Mu Seong Lee; Sei Young Yun; Kyung Mi Shim; Se Eun Kim; Kwangsik Jang Journal: In Vivo Date: 2022 Jul-Aug Impact factor: 2.406
Authors: Stefano Dastoli; Steven Paul Nisticò; Pietro Morrone; Cataldo Patruno; Antonio Leo; Rita Citraro; Luca Gallelli; Emilio Russo; Giovambattista De Sarro; Luigi Bennardo Journal: Pharmaceutics Date: 2022-01-27 Impact factor: 6.321